Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 6, 2004, Pages 1072-1077

  Zhanel, George G ^a,b   Johanson, Christel ^a   Hisanaga, Tamiko ^a   Mendoza, Chris ^a   Laing, Nancy ^a   Noreddin, Ayman ^a   Wierzbowski, Aleksandra ^a   Hoban, Daryl J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

erm(B); Ketolides; mef(A); Respiratory tract infections; S. pneumoniae

Indexed keywords

AZITHROMYCIN; CLINDAMYCIN; KETOLIDE; MACROLIDE; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG HALF LIFE; EPITHELIUM; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; POLYMERASE CHAIN REACTION; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BODY FLUIDS; COLONY COUNT, MICROBIAL; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; EPITHELIUM; HUMANS; KETOLIDES; MACROLIDES; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STREPTOCOCCUS PNEUMONIAE;

EID: 12344323603     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh475     Document Type: Article

References (39)

1. File, T. M. (2002). Appropriate use of antimicrobials for drug resistant pneumonia: focus on significance of β-lactam resistant Streptococcus pneumoniae. Clinical Infectious Diseases 34, Suppl. 1, 17-26.
2. Baer, M., Vuento, R. & Vesikari, T. (1995). Increase in bacteraemic pneumococcal infections in children. Lancet 347, 345-61.
3. Del Beccaro, M. A., Mendelman, P. M., Inglis, A. F. et al. (1992). Bacteriology of acute otitis media: a new perspective. Journal of Pediatrics 120, 81-4.
4. Marston, B. J., Plouffe, J. F., File, T. M. et al. (1997). Incidence of community-acquired pneumonia requiring hospitalization: results of population-based active surveillance in Ohio. Archives of Internal Medicine 157, 1709-18.
5. Schuchat, A., Robinson, K., Wenger, J. D. et al. (1997). Bacterial meningitis in the United States in 1995. New England Journal of Medicine 337, 970-6.
6. Campell, G. D., Jr & Silberman, R. (1998). Drug-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 26, 1188-95.
7. Pallares, R., Linares, J., Vadillo, M. et al. (1995). Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumoniae in Barcelona. Spain. New England Journal of Medicine 333, 474-80.
8. Hoban, D. J., Doern, G. V., Fluit, A. C. et al. (2001). Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program 1997-1999. Clinical Infectious Diseases 32, Suppl. 2, 81-93.
9. Mazzulli, T., Simor, A. E., Jaeger, R. et al. (1990). Comparative in vitro activities of several new fluoroquinolones and β-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 34 467-9.
10. Simor, A. E., Louie, M. & Low, D. E. (1996). Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 40, 2190-3.
11. Thornsberry, C., Ogilvie, P. T., Holley, H. P. et al. (1999). Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrobial Agents and Chemotherapy 43, 2616-23.
12. Whitney, C. G., Farley, M. M. & Hadler, J. (2000). Increasing prevalence of multi-drug resistant Streptococcus pneumoniae in the United States. New England Journal of Medicine 343, 1817-24.
13. Zhanel, G. G., Karlowsky, J. A., Palatnick, L. et al. (1999). Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. Antimicrobial Agents and Chemotherapy 43, 2504-9.
14. Zhanel, G. G., Palatnick, L., Nichol, K. et al. (2003). Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997-2002. Antimicrobial Agents and Chemotherapy 47, 1867-74.
15. Doern, G. V., Hellmann, K. P., Huynh, H. K. et al. (2001). Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000 including a comparison of resistance rates since 1994-1995. Antimicrobial Agents and Chemotherapy 45, 1721-9.
16. Butler, J. C., Hofmann, J., Cetron, M. S. et al. (1996). The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. Journal of Infectious Diseases 174, 986-93.
17. Zhanel, G. G., Dueck, M., Hoban, D. J. et al. (2001). Macrolides and ketolides: a review focusing on respiratory infections. Drugs 61, 443-98.
18. Zhanel, G. G. & Karlowsky, J. A. (1999). Ribosomal resistance: emerging problems and potential solutions. Current Infectious Disease Reports 1, 458-63.
19. Hoban, D. J., Wierzbowski, A., Nichol, K. A. et al. (2001). Macrolide-resistant Streptococcus pneumoniae in Canada from 1998-1999: prevalence of mef(A) and erm(B) and susceptibility to ketolides. Antimicrobial Agents and Chemotherapy 45, 2147-50.
20. Rzeszutek, M., Wierzbowski, A., Hoban, D. J. et al. (2004). A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. International Journal of Antimicrobial Agents 24, 95-104.
21. Zhanel, G. G., Wierzbowski, A., Hisanaga, T. et al. (2004). The use of ketolides in treatment of upper respiratory tract infections. Current Infectious Disease Reports 6, 191-9.
22. Zhanel, G. G., Hisanaga, T., Nichol, K. et al. (2003). Emerging treatments for macrolide resistant bacteria. Expert Opinion on Emerging Drugs 8, 297-321.
23. Hoban, D. J., Zhanel, G. G. & Karlowsky, J. A. (1999). In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Diagnostic Microbiology and Infectious Diseases 35, 37-44.
24. Walsh, F., Carnegy, F., Willcock, J. et al. (2004). Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 53, 793-6.
25. Farrell, D. & Felmingham, D. (2004). Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999-2003. Antimicrobial Agents and Chemotherapy 48, 1882-4.
26. Khair, O. A., Andrews, J. M., Honeybourne, D. et al. (2001). Lung concentrations of telithromycin after oral dosing. Journal of Antimicrobial Chemotherapy 47, 837-40.
27. Muller-Serieys, C., Soler, P., Cantalloube, C. et al. (2001). Bronchopulmonary disposoition of the ketolide telithromycin (HMR 3647). Antimicrobial Agents and Chemotherapy 45, 3104-8.
28. Odenholt, I., Lowdin, E. & Cars, O. (2001). Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrobial Agents and Chemotherapy 45, 23-9.
29. Nicolau, D. P. (2004). Clinical use of antimicrobial pharmacodynamic profiles to optimize treatment outcomes in community-acquired bacterial respiratory tract infections: applications to telithromycin. Expert Opinion in Pharmacotherapy 5, 229-35.
30. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA.
31. National Committee for Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Susceptibility Testing: Supplemental Tables M100-S12. NCCLS, Wayne, PA, USA.
32. Noreddin, A., Roberts, D., Nichol, K. et al. (2002). Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrobial Agents and Chemotherapy 46, 4029-34.
33. Zhanel, G. G., DeCorby, M., Noreddin, A. et al. (2003). Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. Journal of Antimicrobial Chemotherapy 52, 83-8.
34. Tellier, G., Chang, J. R., Asche, C. V. et al. (2004). Comparison of hospitalization rates in patients with community acquired pneumonia treated with telithromycin for 5 or 7 days or with clarithromycin for 10 days. Current Medical Research and Opinion 20, 739-47.
35. Niederman, M. S., Chang, J. R., Stewart, J. et al. (2004). Comparison of hospitalization rates in patients with community acquired pneumonia treated with 10 days of telithromycin or clarithromycin. Current Medical Research and Opinion 20, 740-56.
36. Zhanel, G. G. (2001). Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. Current Infectious Disease Reports 3, 29-34.
37. Jacobs, M. R., Bajaksouzian, S. & Appelbaum, P. C. (2003). Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci. Journal of Antimicrobial Chemotherapy 52 809-12.
38. Drusano, G. (2001). Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Clinical Microbiology and Infection 7, Suppl. 3, 24-9.
39. Odenholt, I., Lowdin, E. & Cars, O. (2001). Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrobial Agents and Chemotherapy 45, 23-9.